Mechanisms of Enhanced (cid:1) -Adrenergic Reserve From Cardiac Resynchronization Therapy

Background —Cardiac resynchronization therapy (CRT) is the first clinical heart failure treatment that improves chamber systolic function in both the short-term and long-term yet also reduces mortality. The mechanical impact of CRT is immediate and well documented, yet its long-term influences on myocyte function and adrenergic modulation that may contribute to its sustained benefits are largely unknown. Methods and Results —We used a canine model of dyssynchronous heart failure (DHF; left bundle ablation, atrial tachypacing for 6 weeks) and CRT (DHF for 3 weeks, biventricular tachypacing for subsequent 3 weeks), contrasting both to nonfailing controls. CRT restored contractile synchrony and improved systolic function compared with DHF. Myocyte sarcomere shortening and calcium transients were markedly depressed at rest and after isoproterenol stimulation in DHF (both anterior and lateral walls), and CRT substantially improved both. In addition, (cid:1) 1 and (cid:1) 2 stimulation was enhanced, coupled to increased (cid:1) 1 receptor abundance but no change in binding affinity. CRT also augmented adenylate cyclase activity over DHF. Inhibitory G-protein (G (cid:2) i ) suppression of (cid:1) -adrenergic stimulation was greater in DHF and reversed by CRT. G (cid:2) i expression itself was unaltered; however, expression of negative regulators of G (cid:2) i signaling (particularly RGS3) rose uniquely with CRT over DHF and controls. CRT blunted elevated myocardial catecholamines in DHF, restoring levels toward control. Conclusions —CRT improves rest and (cid:1) -adrenergic–stimulated myocyte function and calcium handling, upregulating (cid:1) 1 receptors and adenylate cyclase activity and suppressing G i -coupled signaling associated with novel RGS upregulation. The result is greater rest and sympathetic reserve despite reduced myocardial neurostimulation as components underlying its net benefit. ( Circulation . 2009;119:1231-1240.) 0.4 mol/L perchloric acid containing 0.5 mmol/L EDTA and centri- fuged at 5000 rpm at 4°C. Catecholamines were extracted from the supernatant with an alumina extraction procedure and quantified by liquid chromatography with electrochemical detection as described. 24 Concentration was normalized to tissue weight. signaling. Accompa-nying this adrenergic upregulation was a decline in myocardial catecholamines from the higher levels observed in dyssynchronous heart failure hearts. Thus, CRT effectively restored a more normal balance of greater cellular adrenergic responsiveness with reduced chronic sympathetic stimulation. This may play an important role in the long-term efficacy of CRT on clinical symptoms and survival and its interaction with concurrent pharmacological neuroblockade treatment.

[1]  Brian O'Rourke,et al.  Electrophysiological Consequences of Dyssynchronous Heart Failure and Its Restoration by Resynchronization Therapy , 2009, Circulation.

[2]  D. Kass,et al.  Reversal of Global Apoptosis and Regional Stress Kinase Activation by Cardiac Resynchronization , 2008, Circulation.

[3]  W. Wijns,et al.  Endomyocardial upregulation of beta1 adrenoreceptor gene expression and myocardial contractile reserve following cardiac resynchronization therapy. , 2008, Journal of Cardiac Failure.

[4]  W. Wijns,et al.  Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. , 2008, Journal of the American College of Cardiology.

[5]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[6]  W. Tang,et al.  Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. , 2008, Heart rhythm.

[7]  T. Wieland,et al.  Regulator of G-protein signalling 3 redirects prototypical Gi-coupled receptors from Rac1 to RhoA activation. , 2007, Cellular signalling.

[8]  S. Iyengar,et al.  Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy. , 2007, Journal of cardiac failure.

[9]  T. Wieland,et al.  Regulators of G protein signalling: a spotlight on emerging functions in the cardiovascular system. , 2007, Current opinion in pharmacology.

[10]  L. Saul Cardiac Resynchronization Therapy , 2007, Critical care nursing quarterly.

[11]  P. van de Borne,et al.  Sympathetic control after cardiac resynchronization therapy: responders versus nonresponders. , 2006, American journal of physiology. Heart and circulatory physiology.

[12]  David D Spragg,et al.  Pathobiology of left ventricular dyssynchrony and resynchronization. , 2006, Progress in cardiovascular diseases.

[13]  Wei Zhang,et al.  Regulation of cardiomyocyte signaling by RGS proteins: differential selectivity towards G proteins and susceptibility to regulation. , 2006, Journal of molecular and cellular cardiology.

[14]  D. Tilley,et al.  Role of β-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment , 2006, Expert review of cardiovascular therapy.

[15]  Wei Zhang,et al.  Selective Loss of Fine Tuning of Gq/11 Signaling by RGS2 Protein Exacerbates Cardiomyocyte Hypertrophy* , 2006, Journal of Biological Chemistry.

[16]  G. Hasenfuss,et al.  Biventricular Pacing Improves the Blunted Force–Frequency Relation Present During Univentricular Pacing in Patients With Heart Failure and Conduction Delay , 2006, Circulation.

[17]  S. Akhter,et al.  Restoration of myocardial beta-adrenergic receptor signaling after left ventricular assist device support. , 2006, The Journal of thoracic and cardiovascular surgery.

[18]  E. Lakatta,et al.  Subtype-specific alpha1- and beta-adrenoceptor signaling in the heart. , 2006, Trends in pharmacological sciences.

[19]  L. Saccá,et al.  Effects of biventricular pacing on interstitial remodelling, tumor necrosis factor-alpha expression, and apoptotic death in failing human myocardium. , 2006, European heart journal.

[20]  R. Haworth,et al.  Crosstalk of &bgr;-Adrenergic Receptor Subtypes Through Gi Blunts &bgr;-Adrenergic Stimulation of L-Type Ca2+ Channels in Canine Heart Failure , 2005, Circulation research.

[21]  D. Feldman,et al.  Mechanisms of Disease: β-adrenergic receptors—alterations in signal transduction and pharmacogenomics in heart failure , 2005, Nature Clinical Practice Cardiovascular Medicine.

[22]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[23]  J. Conti,et al.  Use of cardiac resynchronization therapy to optimize beta-blocker therapy in patients with heart failure and prolonged QRS duration. , 2005, The American journal of cardiology.

[24]  Andrew P. Kramer,et al.  Short-Term Effects of Right-Left Heart Sequential Cardiac Resynchronization in Patients With Heart Failure, Chronic Atrial Fibrillation, and Atrioventricular Nodal Block , 2004, Circulation.

[25]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[26]  T. Eschenhagen,et al.  Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. , 2003, Cardiovascular research.

[27]  Martin J. Lohse,et al.  What Is the Role of &bgr;-Adrenergic Signaling in Heart Failure? , 2003, Circulation research.

[28]  W. Koch,et al.  Cardioprotection specific for the G protein Gi2 in chronic adrenergic signaling through β2-adrenoceptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Christophe Leclercq,et al.  Regional Alterations in Protein Expression in the Dyssynchronous Failing Heart , 2003, Circulation.

[30]  D. Delurgio,et al.  Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart Failure , 2003, Circulation.

[31]  W. Koch,et al.  The beta-adrenergic receptor kinase in heart failure. , 2003, Journal of molecular and cellular cardiology.

[32]  W. Koch,et al.  Overexpression of wild-type Galpha(i)-2 suppresses beta-adrenergic signaling in cardiac myocytes. , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  T. Wieland,et al.  Expression of ten RGS proteins in human myocardium: functional characterization of an upregulation of RGS4 in heart failure. , 2002, Cardiovascular research.

[34]  R. Page,et al.  Effects of resynchronization therapy on sympathetic activity in patients with depressed ejection fraction and intraventricular conduction delay due to ischemic or idiopathic dilated cardiomyopathy. , 2002, The American journal of cardiology.

[35]  Gregory S. Nelson,et al.  Left Ventricular or Biventricular Pacing Improves Cardiac Function at Diminished Energy Cost in Patients With Dilated Cardiomyopathy and Left Bundle-Branch Block , 2000, Circulation.

[36]  C. Dessauer,et al.  RGS3 is a GTPase-activating protein for g(ialpha) and g(qalpha) and a potent inhibitor of signaling by GTPase-deficient forms of g(qalpha) and g(11alpha). , 2000, Molecular pharmacology.

[37]  E. Lakatta,et al.  The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. , 2000, Circulation research.

[38]  E. Lakatta,et al.  Spontaneous activation of beta(2)- but not beta(1)-adrenoceptors expressed in cardiac myocytes from beta(1)beta(2) double knockout mice. , 2000, Molecular pharmacology.

[39]  B. A. Evans,et al.  Desensitization of cardiac beta-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins. , 1999, Journal of molecular and cellular cardiology.

[40]  C. H. Chen,et al.  Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. , 1999, Circulation.

[41]  D. Sawyer,et al.  Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. , 1999, Circulation.

[42]  D. Kass,et al.  Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. , 1999, Circulation research.

[43]  J. Rottman,et al.  RGS3 and RGS4 are GTPase activating proteins in the heart. , 1998, Journal of molecular and cellular cardiology.

[44]  T. Saikawa,et al.  Mechanism of beta-adrenergic receptor upregulation induced by ACE inhibition in cultured neonatal rat cardiac myocytes: roles of bradykinin and protein kinase C. , 1998, Circulation.

[45]  M. Steinfath,et al.  Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. , 1996, European journal of clinical pharmacology.

[46]  M. Zile,et al.  The cellular basis for the blunted response to beta-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy. , 1993, Journal of molecular and cellular cardiology.

[47]  S. Vatner,et al.  Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. , 1993, The Journal of clinical investigation.

[48]  D. Murphy,et al.  Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. , 1986, Clinical chemistry.